Michael W. Cho

2.3k total citations
36 papers, 1.8k citations indexed

About

Michael W. Cho is a scholar working on Virology, Immunology and Infectious Diseases. According to data from OpenAlex, Michael W. Cho has authored 36 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Virology, 18 papers in Immunology and 13 papers in Infectious Diseases. Recurrent topics in Michael W. Cho's work include HIV Research and Treatment (27 papers), Immune Cell Function and Interaction (17 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Michael W. Cho is often cited by papers focused on HIV Research and Treatment (27 papers), Immune Cell Function and Interaction (17 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Michael W. Cho collaborates with scholars based in United States, United Kingdom and South Korea. Michael W. Cho's co-authors include Dong P. Han, Malcolm A. Martin, Alicia Buckler‐White, Myung K. Lee, Robert A. Ogert, William A. Ross, Adam Penn‐Nicholson, Tatsuhiko Igarashi, Ronald L. Willey and Riri Shibata and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and PLoS ONE.

In The Last Decade

Michael W. Cho

36 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael W. Cho United States 19 1.1k 815 715 421 355 36 1.8k
Constantinos Kurt Wibmer South Africa 12 923 0.9× 972 1.2× 593 0.8× 460 1.1× 207 0.6× 17 1.7k
Alessândra Borsetti Italy 19 1.5k 1.4× 815 1.0× 993 1.4× 587 1.4× 325 0.9× 69 2.2k
Wade Blair United States 26 1.1k 1.0× 1.1k 1.3× 430 0.6× 664 1.6× 458 1.3× 45 2.1k
Tandile Hermanus South Africa 10 679 0.6× 919 1.1× 450 0.6× 389 0.9× 182 0.5× 24 1.5k
Dennis M. Lambert United States 15 1.3k 1.2× 1.2k 1.4× 383 0.5× 640 1.5× 616 1.7× 27 2.3k
Dirk Eggink Netherlands 28 691 0.6× 1.0k 1.3× 845 1.2× 601 1.4× 1.4k 3.9× 84 2.6k
William R. Gallaher United States 19 751 0.7× 792 1.0× 384 0.5× 728 1.7× 577 1.6× 36 2.0k
Hiromi Imamichi United States 27 2.1k 1.9× 1.4k 1.7× 1.2k 1.7× 588 1.4× 571 1.6× 48 3.0k
Michael M. Thomson Spain 34 1.9k 1.8× 1.6k 2.0× 433 0.6× 497 1.2× 849 2.4× 88 2.9k
Yuxing Li United States 25 1.6k 1.5× 605 0.7× 1.3k 1.8× 514 1.2× 393 1.1× 58 2.2k

Countries citing papers authored by Michael W. Cho

Since Specialization
Citations

This map shows the geographic impact of Michael W. Cho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Cho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Cho more than expected).

Fields of papers citing papers by Michael W. Cho

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael W. Cho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Cho. The network helps show where Michael W. Cho may publish in the future.

Co-authorship network of co-authors of Michael W. Cho

This figure shows the co-authorship network connecting the top 25 collaborators of Michael W. Cho. A scholar is included among the top collaborators of Michael W. Cho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael W. Cho. Michael W. Cho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Niu, Ling, et al.. (2021). Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen. Frontiers in Immunology. 12. 637982–637982. 9 indexed citations
2.
Niu, Ling, et al.. (2021). A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain. Frontiers in Immunology. 12. 647934–647934. 39 indexed citations
3.
Nabi, Rafiq, Zina Moldoveanu, Qing Wei, et al.. (2017). Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy. PLoS ONE. 12(7). e0180245–e0180245. 13 indexed citations
4.
Zhao, Chun‐Xia, Fawn Connor‐Stroud, Ho‐Jin Moon, et al.. (2017). Comparison of the vaginal environment in rhesus and cynomolgus macaques pre‐ and post‐lactobacillus colonization. Journal of Medical Primatology. 46(5). 232–238. 5 indexed citations
5.
Cho, Michael W., et al.. (2016). Focal Breast Pain. Academic Radiology. 24(1). 53–59. 17 indexed citations
6.
Habte, Habtom H., et al.. (2015). Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region. Virology. 486. 187–197. 6 indexed citations
7.
Qin, Yali, Adam Penn‐Nicholson, Habtom H. Habte, et al.. (2014). Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence. Virology. 462-463. 363–376. 15 indexed citations
8.
Qin, Yali, et al.. (2014). Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits. Retrovirology. 11(1). 125–125. 6 indexed citations
9.
Hioe, Catarina E., Michael Tuen, Gaia Vasiliver-Shamis, et al.. (2011). HIV Envelope gp120 Activates LFA-1 on CD4 T-Lymphocytes and Increases Cell Susceptibility to LFA-1-Targeting Leukotoxin (LtxA). PLoS ONE. 6(8). e23202–e23202. 32 indexed citations
10.
Nara, Peter L., Gregory J. Tobin, Abhijit Chaudhuri, et al.. (2010). How Can Vaccines Against Influenza and Other Viral Diseases Be Made More Effective?. PLoS Biology. 8(12). e1000571–e1000571. 22 indexed citations
11.
Shi, Wuxian, Jen Bohon, Dong P. Han, et al.. (2010). Structural Characterization of HIV gp41 with the Membrane-proximal External Region. Journal of Biological Chemistry. 285(31). 24290–24298. 32 indexed citations
12.
Han, Dong P., et al.. (2007). Specific Asparagine-Linked Glycosylation Sites Are Critical for DC-SIGN- and L-SIGN-Mediated Severe Acute Respiratory Syndrome Coronavirus Entry. Journal of Virology. 81(21). 12029–12039. 102 indexed citations
13.
14.
Han, Dong P., Adam Penn‐Nicholson, & Michael W. Cho. (2006). Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. Virology. 350(1). 15–25. 162 indexed citations
15.
Han, Dong P., et al.. (2004). Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology. 326(1). 140–149. 56 indexed citations
16.
17.
Lee, Myung K., et al.. (2001). Development of a Safe and Rapid Neutralization Assay Using Murine Leukemia Virus Pseudotyped with HIV Type 1 Envelope Glycoprotein Lacking the Cytoplasmic Domain. AIDS Research and Human Retroviruses. 17(18). 1715–1724. 20 indexed citations
18.
Hu, Yu, Joshua D. Kaufman, Michael W. Cho, Hana Golding, & Joseph Shiloach. (2000). Production of HIV-1 gp120 in Packed-Bed Bioreactor Using the Vaccinia Virus/T7 Expression System. Biotechnology Progress. 16(5). 744–750. 18 indexed citations
19.
Shibata, Riri, Tatsuhiko Igarashi, Nancy L. Haigwood, et al.. (1999). Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys. Nature Medicine. 5(2). 204–210. 441 indexed citations
20.
Lee, Myung K., et al.. (1999). Identification of Determinants of Interaction between CXCR4 and gp120 of a Dual-tropic HIV-1DH12Isolate. Virology. 257(2). 290–296. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Constantinos Kurt Wibmer Breakdown of academic impact, for papers by Alessândra Borsetti Breakdown of academic impact, for papers by Wade Blair Breakdown of academic impact, for papers by Tandile Hermanus Breakdown of academic impact, for papers by Dennis M. Lambert Breakdown of academic impact, for papers by Dirk Eggink Breakdown of academic impact, for papers by William R. Gallaher Breakdown of academic impact, for papers by Hiromi Imamichi Breakdown of academic impact, for papers by Michael M. Thomson Breakdown of academic impact, for papers by Yuxing Li
Rankless by CCL
2026